[Modulation of chemoresistance: methodology of therapeutic trials].
A certain percentage of cancers are primarily or subsequently resistant to chemetherapeutic agents. Several biological mechanisms are implicated in this phenomenon, including multidrug resistance/P-glycoprotein (mdr1/P-gp), resistance related proteins (P-95 and P-110), multidrug resistance associated protein (P-190), iso-enzymes of gluthatione S-transferase, topo-isomerases, glutathione peroxidase and others. mdr1/P-gp overexpression has been studied in many types of cancer. It represents an inducible, transferable and phylogenetically ancestral biological system. It is expressed at the surface of the cell, and in that way, it participates to several normal functions. The recent introduction of modulators/revertants of mdr1/P-gp may change some concepts in using chemotherapy for cancers. The first step is represented by a better knowledge of the cancers which overexpressed mdr1/P-gp, with determination of the best biological technique, including the gold standards. This allows the clinician to clarify the best impact of such a therapeutic way and to define the criteria of modulator selection. Such criteria includes in vitro selection using a panel of sensitive/resistant cell lines, in vivo tests including transgenic mice, nude or SCID mice, and toxicological studies. Choice of modulated drug is easier and depends on the biological target. For mdr1/P-gp, major drugs included doxorubicin and vinca-alkaloids. Due to the fact that some modulators have an influence on the pharmacokinetic parameters of chemotherapeutic drugs, it is important to verify such parameters. The last choice concerns the strategy of drug development with three levels of action: 1) modulation of clinical chemoresistance, intrinsic or acquired one; 2) modulation of biological resistance; 3) leading to the prevention of the amplification of low levels of chemoresistance. A new therapeutic way is born, which takes care of a dynamic aspect of the tumor, and necessitates a new use of chemotherapy.
Rossi
J F
JF
Service d'oncologie-hématologie, CHU Lapeyronie, Montpellier.
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000187:drug effects / Q000235:genetics; D000818:Animals; D018432:Drug Resistance, Multiple / Q000235:genetics*; D019008:Drug Resistance, Neoplasm; D006801:Humans; D066298:In Vitro Techniques; D051379:Mice; D009369:Neoplasms / Q000235:genetics; D009374:Neoplasms, Experimental / Q000235:genetics
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1
Modulation de la chimiorésistance: méthodologie des essais thérapeutiques.